IBD is a group of serious disorders that primarily includes ulcerative colitis (UC) and Crohn’s disease (CD). Both ulcerative colitis (UC) and Crohn’s disease are long-term (chronic) diseases involving inflammation of the gastrointestinal tract. Ulcerative colitis only affects the colon (large intestine), while Crohn’s disease can affect the entire digestive system, from the mouth to the anus.
IBD can significantly affect daily living and can lead to life-threatening complications such as toxic-megacolon or cancer and death. IBD is one of the most prevalent gastrointestinal diseases in the United States. Patients with IBD suffer from a range of uncomfortable and debilitating symptoms including diarrhoea and abdominal pain. IBD can also lead to potentially life-threatening complications such as perforation (rupture) of the bowl and patients with IBD may have an increased likelihood of developing bowel cancer. Bridge is tackling the huge unmet medical need in the treatment of IBD by targeting key inflammatory mechanisms in IBD using a safe and highly effective and targeted peptide delivered with a state-of-the-art nanopolymer drug delivery system (JEL3108).
Ulcerative Colitis is an inflammatory condition, affecting the colon, for which there is a substantial unmet medical need. The aim of drug therapy in UC is essentially two-fold; firstly, to induce remission but secondly (and importantly) prevent subsequent relapses. 5-aminosalicylic acid (5-ASA) formulations are first line therapy and generally well tolerated and effective in inducing remission in some patients, particularly those with mild to moderate disease. However, a substantial proportion of patients need additional therapy to attain remission and moreover, many patients relapse despite chronic 5-ASA therapy. In patients who ‘fail’ 5-ASA treatment, steroids and infliximab are useful at inducing remission. Moreover, azathiprine/6MP and infliximab are also effective at maintaining remission and thereby preventing relapse. However, these medications are far from ideal because they have substantial toxicity and are not effective in many patients.
Although a number of new drugs are being evaluated for UC the majority are for moderate to severe disease. The vast majority of patients with mild to moderate disease may not be well served by these therapies because they will likely carry substantial side-effects or safety concerns that limit their use. Hence, there is a considerable market for a new compound that induces and maintains remission with a safety and toxicity profile that supports chronic use.
JEL3108 is Bridge’s novel nanomedicine that will deliver a unique, potent anti-inflammatory compound that will “switch off” the inflammation in IBD and, with continued therapy, will prevent its relapse. Bridge considers JEL3108 to have considerable potential in the market place, and see it, initially, as an additional therapy on top of 5-ASA in mild-moderate UC.